Auris Medical Holding AG (NASDAQ:EARS) is a clinical-stage biopharmaceutical company developing pharmacotherapies for neurologic disorders of the inner ear. The company’s primary focus is on the development of intranasal betahistine for the treatment of acute vertigo. Oral betahistine dihydrochloride has been prescribed in Europe for decades for all types of vertigo, with an average 26% market share. We initiate at $117.6m or $4.89 per basic share based on a risk-adjusted NPV analysis of these two programs.
AM-125: Intranasal betahistine for acute vertigo
Each year, an estimated 2.6m visits to the emergency department (ED) are associated with acute dizziness and vertigo in the US. Oral betahistine is the most commonly prescribed medication for all types of vertigo in Europe, but was withdrawn from the US market in 1972 due to unsubstantiated efficacy results upon which approval was based. Auris is developing an intranasal formulation of betahistine, bypassing the digestive tract where the compound is readily metabolised to increase effectiveness.
To read the entire report Please click on the pdf File Below..